Area of research
Hepatology · Epidemiology
Research interest
Research interests include Medicine, Internal medicine, Hepatology, Gastroenterology, Chronic hepatitis, and Intensive care medicine.
Chinese Guidelines on the Management of Hepatic Encephalopathy in Cirrhosis (2024)
A real-world study of polyenyl phosphatidylcholine in the management of patients with metabolic dysfunction-associated fatty liver disease in China clinical practice
Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Research Progress of Fecal Microbiota Transplantation in Liver Diseases
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
[Interpretation of the essential updates in guidelines for the prevention and treatment of chronic hepatitis B (Version 2022)].
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China
Correction to: Consensus on the secondary prevention of primary liver cancer
Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey
HBeAg-positive patients with HBsAg < 135IU/ml or HBcrAg < 3.6logU/ml have more chance to be HBsAg loss after nucleos (t)ide analogue cessation
Expert Consensus on Diagnosis and Treatment of End-Stage Liver Disease Complicated with Infections
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries
Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China
Real-World Clinical Outcomes among Individuals with Chronic HCV Infection in China: CCgenos Study
Sofosbuvir/Velpatasvir for Treatment of Hepatitis C Virus in Asia: An Open-Label, Phase 3 Study
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
[Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
APASL consensus statements and recommendation on treatment of hepatitis C
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
Real‐world treatment patterns and clinical outcomes of HCV treatment‐naive patients in China: an interim analysis from the CCgenos study